- Home
- AXSM vs CPRI Comparison
AXSM vs CPRI Comparison
Compare AXSM & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXSM | CPRI |
|---|---|---|
| Founded | 2012 | 1981 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 3.2B |
| IPO Year | 2015 | 2011 |
Fundamental Metrics
Financial Performance| Metric | AXSM | CPRI |
|---|---|---|
| Price | $152.16 | $25.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 11 |
| Target Price | ★ $176.00 | $26.55 |
| AVG Volume (30 Days) | 464.4K | ★ 2.6M |
| Earning Date | 11-03-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $561,263,000.00 | ★ $4,369,000,000.00 |
| Revenue This Year | $66.40 | N/A |
| Revenue Next Year | $56.13 | $2.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 65.83 | N/A |
| 52 Week Low | $75.56 | $11.86 |
| 52 Week High | $158.57 | $28.27 |
Technical Indicators
Market Signals| Indicator | AXSM | CPRI |
|---|---|---|
| Relative Strength Index (RSI) | 58.25 | 51.34 |
| Support Level | $152.41 | $25.05 |
| Resistance Level | $158.56 | $27.00 |
| Average True Range (ATR) | 4.13 | 0.69 |
| MACD | 0.08 | -0.30 |
| Stochastic Oscillator | 55.41 | 16.18 |
Price Performance
Historical ComparisonAbout AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. Capri also owns a third brand, Versace, but has agreed to sell it to Prada. John Idol has served as Capri's CEO since 2003.